Clinical Trial Search

Primary: Overall Response Rate, Defined as the Percentage of Patients With a Confirmed Clinical Response (CR) or Partial Response (PR) — 3 Participants

Primary: Complete Pathologic Response Rate — 0.103; 0.167 proportion of participants

Primary: Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions — 61.07; 65.58; 41.63 percent change of lesion counts

Primary: Changes in Facial Scarring Score — -.50 score on a scale

Primary: Functional Assessment — 100; 100; 100; 100 percentage of Baseline

Primary: Mean Duration of Action of Intervention — 27; 26 minutes

Primary: Intensity of Injection Site Pain — 8.3; 5.7 Score on a scale — p=0.0395

Primary: Mean Percent Change in the Inflammatory (Papules and Pustules) Lesion Count — 61.70; 63.89; 42.22 percent change of lesion counts

Primary: Change in Spinal Cord Excitability as Measured by Percent Change in Soleus H-Reflex From Beginning of Session to End of the Same Session — -3.13 percent change in H-Reflex

Primary: Number of Participants With Non Progression at 4 Months — 3 Participants

Primary: Peak Drug Concentration (Cmax) After Single Dose of NAC — 83.30 µg/mL

Primary: Difference in 6-Minute Walk Distance Between Groups (Control Minus IGF-1) for Change at 6 Months Versus Baseline — 3.4; -5.1 meters — p=0.53

Primary: Mean Serum Sodium — -0.0; -0.4; -0.4; -0.3 mmol/L

Primary: Change in Median Dyspareunia Pain Scores After 4 Weeks Using Study Drug — -1.5; -3 score on a scale — p=0.08

Primary: Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4 — -0.07; -0.14 gram per minute (g/min) — p== 0.0012